AR083760A1 - ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS - Google Patents

ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS

Info

Publication number
AR083760A1
AR083760A1 ARP110104117A ARP110104117A AR083760A1 AR 083760 A1 AR083760 A1 AR 083760A1 AR P110104117 A ARP110104117 A AR P110104117A AR P110104117 A ARP110104117 A AR P110104117A AR 083760 A1 AR083760 A1 AR 083760A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
substituted
hydrogen
carbon atom
attached
Prior art date
Application number
ARP110104117A
Other languages
Spanish (es)
Inventor
Martin Linsell
Ramesh Kasar
James Bradley Aggen
Qing Jane Lu
Tim Church
Heinz E Moser
Phillip A Patten
Dan Wang
Original Assignee
Achaogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achaogen Inc filed Critical Achaogen Inc
Publication of AR083760A1 publication Critical patent/AR083760A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o un estereoisómero o sal farmacéuticamente aceptable del mismo, donde A es un cicloalquilo C3-6 sustituido, donde al menos un sustituyente es un alcohol primario C1-3; B es nulo, -CH=CH-, -CºC- o un fenilo no sustituido; C es -CH=CH-, -CºC- o un fenilo no sustituido, donde si B es -CH=CH entonces C no es también -CH=CH-; R1, R2 y R3 se seleccionan en forma independiente entre hidrógeno y alquilo C1-3 sustituido o no sustituido, o R1 y R2, junto con el átomo de carbono al cual se encuentran unidos, forman un grupo cicloalquilo C3-6 no sustituido, o R2 y R3, junto con el átomo de carbono y Q a los que se encuentran unidos, forman un anillo heterocíclico sustituido o no sustituido, con entre 5 y 8 átomos del anillo, donde 1 - 2 átomos del anillo heterocíclico se seleccionan entre N, O y S; y Q es O ó NR, donde R es hidrógeno o un alquilo C1-3 no sustituido.Reivindicación 18: Una composición farmacéutica caracterizada porque comprende un segundo agente antibacterial y un compuesto de fórmula (1), o un estereoisómero o sal farmacéuticamente aceptable del mismo, donde A es un cicloalquilo C3-6 sustituido, donde al menos un sustituyente es un alcohol primario C1-3; B es nulo, -CH=CH-, -CºC- o un fenilo no sustituido; C es -CH=CH-, -CºC- o un fenilo no sustituido, donde si B es -CH=CH entonces C no es también -CH=CH-; R1, R2 y R3 se seleccionan en forma independiente entre hidrógeno y alquilo C1-3 sustituido o no sustituido, o R1 y R2, junto con el átomo de carbono al cual se encuentran unidos, forman un grupo cicloalquilo C3-6 no sustituido, o R2 y R3, junto con el átomo de carbono y Q a los que se encuentran unidos, forman un anillo heterocíclico sustituido o no sustituido, con entre 5 y 8 átomos del anillo, donde 1 - 2 átomos del anillo heterocíclico se seleccionan entre N, O y S; y Q es O ó NR, donde R es hidrógeno o un alquilo C1-3 no sustituido.Claim 1: A compound characterized in that it is of formula (1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein A is a C3-6 substituted cycloalkyl, wherein at least one substituent is a C1-3 primary alcohol; B is null, -CH = CH-, -C ° C- or an unsubstituted phenyl; C is -CH = CH-, -C ° C- or an unsubstituted phenyl, where if B is -CH = CH then C is also not -CH = CH-; R1, R2 and R3 are independently selected from hydrogen and substituted or unsubstituted C1-3alkyl, or R1 and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-6 cycloalkyl group, or R2 and R3, together with the carbon atom and Q to which they are attached, form a substituted or unsubstituted heterocyclic ring, with between 5 and 8 ring atoms, where 1-2 atoms of the heterocyclic ring are selected from N, O and S; and Q is O or NR, wherein R is hydrogen or an unsubstituted C1-3 alkyl. Claim 18: A pharmaceutical composition characterized in that it comprises a second antibacterial agent and a compound of formula (1), or a stereoisomer or pharmaceutically acceptable salt of the same, where A is a substituted C3-6 cycloalkyl, where at least one substituent is a C1-3 primary alcohol; B is null, -CH = CH-, -C ° C- or an unsubstituted phenyl; C is -CH = CH-, -C ° C- or an unsubstituted phenyl, where if B is -CH = CH then C is also not -CH = CH-; R1, R2 and R3 are independently selected from hydrogen and substituted or unsubstituted C1-3alkyl, or R1 and R2, together with the carbon atom to which they are attached, form an unsubstituted C3-6 cycloalkyl group, or R2 and R3, together with the carbon atom and Q to which they are attached, form a substituted or unsubstituted heterocyclic ring, with between 5 and 8 ring atoms, where 1-2 atoms of the heterocyclic ring are selected from N, O and S; and Q is O or NR, where R is hydrogen or an unsubstituted C1-3 alkyl.

ARP110104117A 2010-11-10 2011-11-04 ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS AR083760A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41231110P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
AR083760A1 true AR083760A1 (en) 2013-03-20

Family

ID=46317476

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104117A AR083760A1 (en) 2010-11-10 2011-11-04 ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS

Country Status (14)

Country Link
EP (1) EP2638006A1 (en)
JP (1) JP2014501716A (en)
KR (1) KR20140023869A (en)
CN (1) CN103298780A (en)
AR (1) AR083760A1 (en)
AU (1) AU2011367819A1 (en)
BR (1) BR112013011693A2 (en)
CA (1) CA2817211A1 (en)
EA (1) EA201390626A1 (en)
IL (1) IL226270A0 (en)
MX (1) MX2013005200A (en)
SG (1) SG190243A1 (en)
TW (1) TW201249786A (en)
WO (1) WO2012154204A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765585B (en) 2007-06-12 2017-03-15 尔察祯有限公司 Antiseptic
EP2847162A1 (en) * 2012-05-09 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
AR097617A1 (en) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd ANTIBACTERIAL DERIVATIVES OF 2H-INDAZOL
EP3083567B1 (en) 2013-12-19 2018-03-07 Idorsia Pharmaceuticals Ltd Antibacterial 1h-indazole and 1h-indole derivatives
AR099612A1 (en) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd ANTIBACTERIAL DERIVATIVES OF 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA
US9539305B1 (en) 2014-03-14 2017-01-10 Fleurir Abx Llc Pristinamycin compositions, LpxC compositions, their improvements, and combinations thereof
CA2948077A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
AR102687A1 (en) 2014-11-19 2017-03-15 Actelion Pharmaceuticals Ltd ANTIBACTERIAL BENZOTIAZOL DERIVATIVES
CN107001295B (en) 2014-12-16 2021-02-02 诺华股份有限公司 Isoxazole hydroxamic acid compounds as LpxC inhibitors
ES2961564T3 (en) 2016-04-25 2024-03-12 Univ Duke Benzoylglycine derivatives and methods of preparation and use thereof
CA3026356A1 (en) 2016-06-14 2017-12-21 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
TW201803847A (en) 2016-06-23 2018-02-01 美商爾察禎有限公司 Antibacterial agents
CN112074507B (en) * 2018-02-10 2023-09-05 山东亨利医药科技有限责任公司 Compounds as Antibiotics
CN110563611B (en) * 2019-09-19 2021-02-02 中国医学科学院医药生物技术研究所 Hydroxamic acid derivative and preparation method and application thereof
CN113957098A (en) * 2021-09-13 2022-01-21 湖南工业大学 Application of providencia bacterial strain in preparation of divalent manganese oxidant
CN116730870B (en) * 2023-08-08 2023-10-13 中国医学科学院医药生物技术研究所 Hydroxamic acid compound or pharmaceutically acceptable salt thereof, application and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
AU5426398A (en) 1996-10-28 1998-05-22 Versicor Inc Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US6716878B1 (en) 1999-04-09 2004-04-06 Vernalis (Oxford) Limited Antimicrobial agents
CN1777577B (en) 2003-01-08 2011-07-06 诺华疫苗和诊断公司 Antibacterial agents
DE102006032709A1 (en) 2006-07-14 2008-01-17 BSH Bosch und Siemens Hausgeräte GmbH Airborne food mill
CN101209974A (en) * 2006-12-31 2008-07-02 天津药物研究院 Hydroxamic acids derivatives and use thereof
CN101765585B (en) * 2007-06-12 2017-03-15 尔察祯有限公司 Antiseptic
WO2011005355A1 (en) * 2009-05-07 2011-01-13 Achaogen, Inc. Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
AU2011243597B2 (en) * 2010-04-20 2014-05-08 Taisho Pharmaceutical Co., Ltd. Novel hydroxamic acid derivative

Also Published As

Publication number Publication date
KR20140023869A (en) 2014-02-27
JP2014501716A (en) 2014-01-23
MX2013005200A (en) 2013-06-28
IL226270A0 (en) 2013-07-31
CA2817211A1 (en) 2012-11-15
WO2012154204A1 (en) 2012-11-15
EP2638006A1 (en) 2013-09-18
TW201249786A (en) 2012-12-16
AU2011367819A1 (en) 2013-05-02
SG190243A1 (en) 2013-06-28
CN103298780A (en) 2013-09-11
EA201390626A1 (en) 2013-12-30
BR112013011693A2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
AR083760A1 (en) ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS
AR092269A1 (en) SULFAMOILARILAMIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
AR085615A1 (en) USEFUL FLUOROPIRIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY32490A (en) BETA-SECRETASA INHIBITORS
PE20160608A1 (en) SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
CL2012000999A1 (en) Substituted pyrazolospiroketone derivative compounds, acetyl-coa carboxylase inhibitors; pharmaceutical composition comprising them; use to treat or delay the progression or onset of type 2 diabetes, non-alcoholic fatty liver (hgna), or hepatic insulin resistance.
AR092955A1 (en) ANTAGONISTS OF OREXINE RECEIVERS WHICH ARE DERIVED FROM [ORTO BI- (IET-) ARIL] - [2- (META BI- (IET-) ARIL) -PIRROLIDIN-1-IL] -METANONA
CO6251209A2 (en) BORO CYCLE ESTERS AND COMPOSITIONS CONTAINING THEM
RU2012140961A (en) DERIVATIVE OF 1,3,4,8-TETRAHYDRO-2H-PYRIDO [1,2-a] PYRAZINE AND ITS APPLICATION AS AN HIV INTEGRASE INHIBITOR
CR11683A (en) PIRIDINES AND PIRAZINAS AS P13K INHIBITORS
AR072261A1 (en) PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS.
AR072952A1 (en) 2-IMINO-3-METHYL-PIRROLOPIRIMIDINONA PHENYL-REPLACED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE
CO6620055A2 (en) Certain amino-pyrimidines, compositions thereof and methods for the use thereof
AR067757A1 (en) IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS.
AR083870A1 (en) HIV REPLICATION INHIBITORS
BR112016010080A8 (en) pyrazolopyrimidine compounds, pharmaceutical composition and their use
ECSP088965A (en) 2-THIOXANTINE DERIVATIVES THAT ACT AS INHIBITORS OF THE MPO
ECSP13012363A (en) DERIVATIVES OF IMIDAZOPIRIDINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION IN THERAPEUTICS
ES2626801T3 (en) Triazolopyridine compounds as pde10a inhibitors
AR106652A1 (en) COMPOUNDS TO TREAT AMIOTROPHIC LATERAL SCLEROSIS
AR085549A1 (en) TRIAZOLIL PIPERAZINA AND TRIAZOLIL PIPERIDINA DERIVATIVES REPLACED AS MODULATORS OF g SECRETASE
PE20181304A1 (en) INDEOL N-SUBSTITUTE DERIVATIVES AS MODULATORS OF PGE2 RECEPTORS
AR081426A1 (en) PIRAZOL DERIVATIVES INHIBITORS OF THE SIGMA RECEIVER
AR067613A1 (en) PK-DNA INHIBITORS, USE AND SYNTHESIS OF THE SAME
AR081725A1 (en) DERIVATIVES OF OXADIAZOL, PROCESS OF PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM AND ITS USE IN THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
FA Abandonment or withdrawal